Boston, MA (PRWEB) January 19, 2015
Cambridge Biomedical Inc announces collaboration with XenTech SAS based in Evry, France to jointly market CRO services to the biotech and pharmaceutical market in the USA and Europe.
Dr. John Reddington, COO of Cambridge Biomedical, commented that “XenTech’s patient-derived primary tumor Xenograft models combined with the experience of Cambridge Biomedical in bioanalytical assay development enables us to provide a cohesive offering from Development through to Phase IV. This collaboration further enables us to provide critical solutions to meet the product development needs of our partners in the burgeoning healthcare community.”
“Cambridge Biomedical and XenTech have the same scientific DNA,” commented Dr. Pascal Leuraud, XenTech Chief Operating Officer.
“This mean that for both partners, the quest for best science drives our CRO activity,” he said.
“We believe this collaboration will open up access to new customers in both the biotech and pharma sectors and allow both partners to cross-fertilize our customer portfolios in the US and Europe,” said Dr. Leuraud.
Cambridge Biomedical, based in Boston, Massachusetts, supports sponsors by developing customized assays for small and large molecules, biomarkers, and other critical analytes, along with validation and sample testing in our CLIA certified and CAP accredited, GLP/GCLP compliant facilities,
The Company has extensive expertise in technology transfer, assay development, optimization and validation. It also offers specific services in analytical support for PK/PD studies, biomarker development, clinical assay development, assay validation, specimen analysis, and testing services in support of clinical trial and drug or device development.
Our personalized project management approach, along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensure we meet our client’s product development timelines.
XenTech is a highly innovative French-based biotech laboratory and CRO specializing in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX), which closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, and genomics and drug response.
XenTech is known worldwide for its renowned oncology translational platform and its unique panel of patient-derived breast cancer xenografts and its extremely experienced scientific team.
Since its foundation in April 2006, XenTech has assembled one of the world’s most impressive collections of PDX models that are extensively characterized by and associated with molecular data, including gene expression, copy number data, and manually curated mutations. Its preclinical platform is of considerable value to translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine.
XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.
John Reddington PhD DVM
Chief Operating Officer
Pascal Leuraud PhD
Chief Operating Officer